Thursday, Aug 6, 2026
12:00 CEST (Berlin, UTC+2) | 14:00 GST (Dubai, UTC+4) | 15:30 IST (Delhi, UTC+5:30) | 17:00 WIB (Jakarta, UTC+7) | 06:00 EDT (New York, UTC−4)
CAR-T cell therapy has revolutionized the treatment of hematological malignancies, yet solid tumors remain limited by complex biological barriers. Advances in cell engineering, synthetic biology, and immune modulation are enabling CAR-T cells to overcome immune suppression, improve persistence, and enhance tumor targeting. Integrating innovations in receptor design, tumor microenvironment remodeling, and translational research is accelerating next-generation cellular therapies, shaping the future of precision immunotherapy for solid tumors.
Key Takeaways
● Understand biological barriers in solid tumors
● Explore innovative CAR-T engineering
● Gain translational and clinical insights
● Envision the future of precision immunotherapy
● Digital certificate of participation and free sample
The Minds Behind Innovation
● Cell and molecular biologists
● Oncology and translational medicine professionals
● Cell therapy and immunotherapy researchers
For inquiries: events@elabscience.com
Speaker
Dr. Faheem Ahmed Khan
Senior Researcher
Stem Cell & Cancer Research (SCCR) Indonesia
An internationally experienced researcher in stem cell biology, molecular immunology, and cancer immunotherapy, Dr. Faheem Ahmed Khan has held academic, research, and editorial appointments across Indonesia, Thailand, Pakistan, China, and Switzerland, including Associate Professor at Universitas Agung Putra Indonesia (UAPI), Affiliated Researcher at Chulalongkorn University, Thailand, and Associate Editor of Frontiers in Cell and Developmental Biology (Lausanne, Switzerland). His research integrates CRISPR/Cas9 genome engineering and tumor microenvironment modulation to advance next-generation CAR-T cell therapies for solid tumors. Dr. Khan has authored close to 100 Scopus-indexed publications, secured multiple nationally funded research grants, and led international collaborative research that drives innovation in translational cancer immunotherapy.
